Tempus HRD test: Flashcards
Tempus HRD is an “add-on” option.
True
For breat specifically, does it need to be added on xT with a normal match? Yes or no.
Yes
Any other cancer type, it can be xT solid tumor only, T or F?
True
Assesing a tumor for HRD, how do we do this?
1) Analyzing the tumor for presence of variants in HRR genes (BRCA1/2)
2) Genomic instability score
3) Genome-wide loss of heterozygosity
4) RNA expression
5) RAD51 funcational assays
What methods does Tempus currently utilize?
1) Presence of variants in HRR genes
2) Genome-wide loss of heterozygosity
3) RNA expression
Why does the presence of variants in the HRR gene matter?
Beccause they are the basis for the FDA approved list.
What about genome-wide?
reverts back to the two-hit hypothesis
RNA expression?
Using RNA allows us to identify a RNA transcript that’s independent of the genomic DNA status.
Breast and Ovarian:
Tempus will use the GWLOH test for reporting HRD status in those cancer types.
HRD-DNA test for these two**
Prostate and Pancreatic:
RNA expression may be a good method
HRD-RNA test for these two**
Is assessment for the presence of HRR variants always part of the xT?
Yes. Regardless of the cancer type.
Tempus HRD/DNA report:
- The status is either “positive” or “ not detected”
- percentage of GWLOH w/ reference to tumor subtype is provided
- somatic or germline variants at the bottom are reported. Detected in 23 HRR pathway genes.
HRD-DNA
- Breast, Ovarian cancers
- Available as Add-on, xT solid tumor+Normal
- Required sample: 40%
HRD-RNA
- All other cancers
- xT solid tumor+ norml match
- xT solid tumor only
- Required sample: 30%
Biomarkers utlized for HRD-DNA:
- DNA GWLOH or evidence of biallelic BRCA1/2 loss
Biomarkers utlizied for HRD-RNA:
- 20,000 genes (mRNA expression)
Source of data for HRD-DNA:
GWLOH: Copy number losses in DNA
- BRCA 1/2 loss: xT sequencing
Source of data for HRD-RNA:
RNA sequencing
T or F, there is only ONE Tempus HRD test for clinicians to order:
True, the difference is what we do internally once we recieve the order and determine the cancer type.
Which of the following methods is NOT utilized by Tempus to assess tumors for HRD?
Genomic instability score
Which of the following statements about Tempus HRD are false?
- is a standalone test order option
- additional specimen must be submitted to perform HRD
this HRD status is determined by expression score generated from full transcriptome :
HRD-RNA
this HRD status is determined by genome-wide LOH of evidence of biallelic BRCA 1/2 loss
HRD- DNA
Match the cancer type with the threashold is must reach for a “positive” HRD status to be reported:
Breast- 21% LOH
Ovarian - 17% LOH
Prostate - RNA expression score of 50 or greater
